Loading stock data…
$25.55-1.61 (-5.93%)
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases.
vTv Therapeutics Inc. in the Healthcare sector is trading at $25.55 with a market capitalization of $130M. Wall Street consensus targets $56.00 (7 analysts), implying a +119.2% move over the next 12 months. The stock is currently 42% below its 52-week high of $44.00, remaining 24.4% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 30 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0↓ | $36.84M | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$13.93M↓ | $23.26M↑ | -$7.88M↑ | -$10.70M↓ | -$7.72M |
| Net Income | -$13.05M↓ | $24.13M↑ | -$7.14M↑ | -$8.70M↓ | -$6.05M |
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an o...